We Legalized It. So Why Does It Still Feel Broken? An Honest Look at the State of American Cannabis (2026)| Workmans Relief

Seventy percent of Americans support full legalization. Not one state has reversed course. And the industry built on all that goodwill has lost 97 percent of its investor value. Here’s an honest look at what legalization got right, what it got wrong, and why the everyday consumer keeps winning anyway.

Here is a genuinely strange set of facts. About 70 percent of Americans now support full cannabis legalization. Around 88 percent support medical use. Not a single state that has legalized has ever reversed course, not once, not even partially. The industry is worth north of 30 billion dollars. By every measure of public opinion, this fight is over, and the reformers won it decisively.

And yet. Cannabis exchange-traded funds have lost roughly 97 percent of their value since their peak in early 2021. Dispensary owners across the country are drowning in red ink. Investors have been sitting on their hands for five straight years. There are 39 different state programs, none of which agree with each other on much of anything. And the plant remains federally scheduled in a category that says it has no accepted medical use, a claim that would be funny if it weren’t so consequential.

So how does an industry win the argument and lose the business? That’s the question a lot of people who have spent their careers in this space are asking right now, and the answers are more interesting and more honest than the usual hot takes suggest.

The Hearts and Minds Were Won. The Structure Was Not.

Keith Stroup founded NORML in 1970, back when Gallup had only just started bothering to ask Americans how they felt about legalization. The answer then was 12 percent. Fifty-six years later it’s around 70 percent. That is one of the more dramatic reversals in the history of American public opinion on any issue, and Stroup’s read on it is straightforward: the movement convinced the majority of Americans that prohibition was more harmful than the plant itself. Not that the plant is harmless. That prohibition was worse. That’s a different and more defensible argument, and it’s the one that won.

Stroup also makes a point that gets lost in the current doom cycle. Not a single state has reversed its legalization or its medical program. Not one. In American politics, where policies get repealed and re-repealed constantly, that kind of durability is remarkable. The anti-cannabis voices that remain are loud, but as Stroup puts it, they no longer represent many people. The public verdict is in and it has held.

The problem, according to Adam Smith of the Marijuana Policy Project, is what got built on top of that victory. “We misunderstood when we legalized state by state. We misunderstood that legalizing was not going to immediately replace the illicit market.” The state-by-state approach was a reaction to federal inaction, and it produced exactly what you’d expect from 39 separate improvised systems: inefficiency, incoherence, and costs that make it nearly impossible to operate profitably.

California is the case study. The state passed medical legalization in 1996 and largely left implementation to local governments. When adult use passed later, roughly 60 percent of the state’s counties hadn’t allowed medical in the first place, so most of them didn’t allow adult use either. The result is a state that is famous worldwide for legal cannabis where the majority of the geography has no legal storefront. That’s not a legalization failure. That’s a structural design failure, and it’s been replicated in various forms across the country. The full text and history of California’s Proposition 64 is public if you want to see how the sausage was made, and the state’s Attorney General’s office maintains the medicinal cannabis guidance that governs the older program.

Smith’s larger critique is the one worth sitting with. “What we didn’t set up is a rational cannabis policy that is based on public health, public safety and public access. So the industry rose, and then the industry crashed.” The movement was about ending an unjust prohibition. The industry that followed was about capturing a market. Those are not the same goal, and the second one swallowed the first.

The Money Story: Irrational Exuberance Meets Reality

The financial collapse has its own logic, and it’s not mysterious. Steve Schain, an attorney working in cannabis banking and finance, dates the peak to the first quarter of 2021, when pandemic conditions gave cannabis stocks an artificial boost and everything traded at all-time highs. The fall since then has been on the order of 97 percent in cannabis ETFs. His diagnosis is blunt: the industry got ahead of itself, and there was irrational exuberance about a future that could never have met the predictions.

Morgan Paxhia, who co-founded one of the largest funds in the cannabis space, describes a pattern that repeats with almost mechanical predictability. “People get excited. They love to see pretty plants. That often leads to an overbuild of capacity. In almost every single market we see just inevitably too much capacity relative to the demand, which leads to price compression, which leads to companies that have high cost structures going out of business. Every state is watching this happen over and over again on repeat.”

Schain’s harshest observation is about the operators themselves. He describes a generation of entrepreneurs who borrowed heavily without any realistic plan to repay, who wanted their money out in eighteen months, and who never intended to build anything durable. His line about it lands hard: the phrase “serial entrepreneur” now means getting in with as little money as possible and getting out fast. “No one said I’m building this for my grandkids.”

That’s the part of this story that should matter to consumers, because it explains a lot about the product quality problems that have dogged this space. A market flooded with operators who are optimizing for a quick exit is a market where corners get cut, testing gets treated as an obstacle rather than a responsibility, and the customer is a means to an end rather than the point of the whole exercise. Paxhia’s advice to his own portfolio companies is the antidote: “Just build patiently, build profitably, and at some point, you will be paid for that.”

The Counter-Argument: This Isn’t a Backlash, It’s a Maturation

Not everyone in the industry reads the current moment as a crisis. Ricardo Baca, who became the first cannabis columnist at a mainstream American newspaper back in 2013, offers a more measured take. “I don’t know that I see a backlash. I see the inevitable maturation of a complex, federally illegal industry that finally has years under its belt so we can actually learn what this really looks like.”

That framing is worth taking seriously. Every emerging industry in American history has followed a version of the same arc. Boom, overbuild, bust, consolidation, and then a slower, healthier equilibrium where the operators who actually know what they’re doing survive and the tourists go home. Railroads did it. Radio did it. The internet did it twice. Cannabis is doing it now. The wreckage looks catastrophic from the inside, but from a distance it looks like a market figuring out what it actually is.

Scott Vasterling, who runs a sun-grown farm operation, sees something even more optimistic in the current moment. “What I am seeing is that the state of the market in cannabis is actually becoming more normalized than it ever has been. We’re seeing the proliferation of hemp-derived products now, and we can have the conversation about regulation and testing and things, and the needs for those types of quality control measures that I think are critically important to the industry. But it’s the same plant, right? So I think that what that’s doing is it’s normalizing cannabis as an agricultural crop.”

That’s the shift that matters most. Not cannabis as a countercultural symbol, not cannabis as a speculative asset class, but cannabis as an agricultural crop with quality standards, testing requirements, and the same expectations of consistency that apply to every other thing Americans grow and sell. Vasterling also describes something encouraging happening on the ground: farmers sharing genetics, operators collaborating instead of hustling each other, and the in-fighting of the green rush era giving way to actual professional relationships. Boring, in the best possible way. Boring is what a mature industry looks like.

An Honest Word About Risks, Because Pretending Otherwise Isn’t Credible

Here’s where a lot of cannabis industry commentary loses the plot, and where we’re going to do the opposite. This plant is not risk-free, and any brand that tells you otherwise is selling you something. The research on the risks is real, published in serious journals, and deserves to be part of an honest conversation rather than dismissed as prohibitionist propaganda.

The New England Journal of Medicine has published a substantial review on cannabis-related disorders and toxic effects that documents genuine clinical concerns, including dependence, effects in adolescents, and interactions with mental health conditions. The Journal of the American Heart Association has published research on associations between cannabis use and cardiovascular outcomes that raises real questions worth taking seriously. These are not fringe sources. They are among the most respected medical journals in the world, and their findings belong in this conversation.

Baca makes the point well from inside the industry: “You have really valuable medical research coming out about the efficacy of cannabis, but also about the risks, which are real, because this plant is not without its risks.” He also notes, correctly, that a lot of early-stage research with small sample sizes is being taken too seriously in both directions, by boosters and critics alike. What the field needs is larger studies, better methodology, and the patience to let the evidence accumulate rather than cherry-picking whatever confirms the position you already held.

Our position on this is simple. The risks are real and consumers deserve to know about them. So are the benefits, which are also increasingly well documented in serious journals, including the growing research on cannabis and sleep quality and the anti-inflammatory effects documented in dermatological reviews. Grown adults are capable of weighing both sides and making their own informed decisions. That’s what the research is for. Anyone who tells you this plant is a miracle with no downsides is as unreliable as anyone who tells you it’s a menace with no upside. Reality lives in the middle, and it’s more interesting than either extreme.

The Part That Explains Why Your Hemp Products Are Doing Fine

Here’s the thing that most of the doom coverage misses entirely. While the state-licensed marijuana industry has been putting itself through a brutal boom-bust cycle, the federally legal hemp market has been quietly building something more stable on a completely different legal foundation.

The reason is structural. Hemp was federally legalized nationwide under the 2018 Farm Bill. That means hemp-derived products operate under one federal framework rather than 39 conflicting state ones. They have access to normal banking. They ship across state lines. They aren’t subject to the punishing federal tax provisions that have strangled state-licensed marijuana businesses. None of the specific structural problems that Smith, Schain, and Paxhia describe apply in the same way. It’s a different market with a different set of rules, and those rules happen to be dramatically more workable.

This is why the CBD topical you buy for your sore back, the tincture in your medicine cabinet, and the federally compliant hemp gummy in your kitchen drawer have been steadily available and steadily improving while the headlines have been full of dispensary bankruptcies. They’re not part of that story. They’re part of a parallel one that has been much less dramatic and much more functional.

That’s not a victory lap. The hemp market has its own regulatory challenges working through the system, and plenty of bad actors have taken advantage of the looser oversight to sell junk. But structurally, the hemp side of this plant has been doing exactly what Vasterling described: normalizing as an agricultural product, building quality control expectations, and serving customers without the boom-bust theatrics.

What Actually Fixes This

Nobody in this conversation has a magic answer, but a few themes keep surfacing from people who have been at it the longest, and they’re worth noting because they’re unglamorous and probably correct.

The first is regulatory coherence. Suehiko Ono, an attorney working with Massachusetts cultivators, describes a system where regulators pile on costs that no other business in the world has to contend with, often without understanding the operational realities of what they’re regulating. He points to New York, where regulators misinterpreted school-distance requirements and voided a batch of dispensary licenses as a result. That’s not malice. That’s a regulatory apparatus being asked to do a job it has never done before, without federal guidance, and getting the details wrong. Ono’s point is that the over-regulation ultimately harms the operators and the consumers both, because somebody pays for all that compliance cost, and it’s usually the person at the register.

The second theme is patience. Paxhia’s advice to build patiently and build profitably runs directly against everything the green rush encouraged. The operators who survive this shakeout are going to be the ones who treated it like a real business from the start, with real cost discipline, real quality standards, and a plan that extends past the next funding round.

The third theme, and the one Paul Armentano of NORML raises, is that none of this progresses on autopilot. “I think we’re in an environment where, because of our past successes, many people among the public are no longer as engaged in this issue as they once were. They think that legalization at this point is just sort of a fait accompli, that it’s just going to kind of happen on its own, not understanding that social and political changes really only happen when there’s advocates who are consistently and diligently advocating for those changes.” Winning the argument is not the same as finishing the work. That’s true of most things worth doing.

Building It for the Grandkids

Of everything in this conversation, the line that stuck with us hardest was Schain’s observation about the industry’s entrepreneurs: “No one said I’m building this for my grandkids.”

That’s the whole problem in nine words. An industry full of people optimizing for an exit is an industry that produces bad products, cuts corners on testing, treats regulation as an obstacle to route around, and leaves the customer holding whatever’s left when the founders cash out. The wreckage that Smith and Schain and Paxhia describe is not primarily a regulatory failure or a market failure. It’s a failure of intent. A lot of people showed up to extract value from this plant rather than to build something worth keeping.

That’s not everyone, obviously. Vasterling’s description of farmers sharing genetics and operators building actual relationships is what the other version looks like. There have always been people in this space who treated it as a craft and a responsibility rather than a payday. They’re the ones still standing.

For our part, we’ll say plainly where Workman’s Relief comes down on this. We’re not a startup chasing an exit. We’re a manufacturer. We own our facility in Wisconsin, we grow USDA Certified Organic hemp on American soil, we run every batch under our own GMP-certified roof, and we publish a Certificate of Analysis for every single product so you can see exactly what you’re getting. That’s not a marketing posture. It’s the operational reality of a company that intends to be here in twenty years serving the same working people it serves today.

The industry’s mess isn’t our mess. We built outside of it on purpose, in the federally legal hemp lane, with an old-fashioned manufacturing philosophy that treats quality control as the entire point rather than a compliance expense. When the shakeout finishes and the tourists have gone home, the companies left standing are going to be the ones who were building for the long haul the whole time. We intend to be one of them.

The Honest Verdict

So did legalization fail? No. Legalization worked. Public opinion moved 58 points in 55 years. Not a single state has gone backward. Millions of Americans have legal access to a plant that people used to go to prison over. The American dad who can now talk openly with his kids about responsible cannabis use is living in a country his own father couldn’t have imagined. That’s not failure. That’s one of the more complete policy reversals in modern American history.

What failed is the business architecture that got improvised on top of it under impossible conditions, with 39 conflicting rulebooks, no federal coherence, a tax code designed to punish, and a flood of capital chasing a story rather than a business. That’s a genuinely hard problem, and it’s going to take another decade of unglamorous work to sort out. Meanwhile the underlying thing, the plant, the research, the consumers, keeps chugging along regardless of what the stock chart says.

America has always been messy about the things it eventually gets right. We argue, we overbuild, we crash, we sue each other, we regulate badly and then better, and somewhere in all that noise the thing gets built anyway. That’s not a bug in the American system. That’s how it has always worked. Cannabis is just the current one going through it.

In the meantime, the people who just want a clean, honest, tested product for their sore back or their bad night of sleep don’t have to wait for any of it to resolve. That option already exists. It’s been here the whole time, quietly working, while everyone was watching the fireworks.

Browse the full Workman’s Relief lineup →

Subscribe & Save | Veterans & First Responders: 15% Off | View Our Certificates of Analysis | Find a Retail Location